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abatacept, tocilizumab) for the treatment of moderate-to-severe active rheumatoid 
arthritis (RA) in Greece. Methods: A budget impact model was adapted from a third-
party payer perspective (National Organization for Healthcare Services Provision 
[EOPYY]) to evaluate economic aspects of RA treatment over 5 years (2014–2018). 
The model assumed Greek epidemiological data and local reimbursement require-
ments. Two main scenarios, following either a conservative or an increased market 
uptake of CZP in the Greek health care market, were estimated and individually 
compared to the current market trend scenario, which incorporates original biologics 
erosion from biosimilars entry in the coming year. Costs pertaining to drug acquisi-
tion, administration (only for intravenous drugs), and monitoring were included in 
the analysis and corresponded to 2014 costing year. Officially published sources were 
used to derive unit costs. The outcome measures were the annual cost of treatment 
with bDMARD presented as total cost and disaggregated by drug cost, administration 
cost and monitoring cost, as well as the incremental cost savings per year. Results: 
Comparing CZP current versus conservative market uptake scenarios, the total budget 
was slightly increased by € 0.05 million. In contrast, comparing CZP current versus 
increased market uptake scenarios, the total budgetary savings were € 0.23 million. In 
the latter comparison setting, the cost savings were attributed to reduced drug and 
administration costs. More specifically, the greater replacement of an intravenously 
administered bDMARD (infliximab) conduced to the greater reduction of adminis-
tration costs than in the former comparison setting (cost savings: € 0.17 vs. € 0.14 
million). ConClusions: A potential increased use of CZP treatment was shown to 
be associated with cost savings over the next 5 years in Greece.
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objeCtives: About 2.79% of patientswith rheumatoid arthritis (RA) in Russia receive 
TNF-α inhibitors; this value may vary significantly and depends on limitations of 
regional budgets. In this respect, the aim of our study was to conduct a compara-
tive pharmacoeconomic analysis of the most prevalent TNF-α inhibitors in Russian 
patients with rheumatoid arthritis and intolerance or inadequate response to con-
ventional basic therapy. Methods: An pharmacoeconomic model was developed 
based on the data from indirect comparison of anti-TNF-α agents. The model consid-
ers the use of infliximab, etanercept, certulizumab pegol, adalimumab in patients 
with RA who lost response to conventional basic therapy. Cost-effectiveness and 
costs of TNF-α inhibitors for health care budget were estimated. The cost analysis 
included costs of pharmacotherapy. Infliximab and etanercept are included into the 
list of vital and essential medicines and were considered as accepted technologies 
in budget impact analysis: certulizumab pegol and adalimumab were novel tecnolo-
gies in our model. A 24-weeks horizon was adopted. Sensitivity analysis (SA) was 
performed by changing costs of medicines Results: the costs of therapy in certuli-
zumab pegol and etanercept groups were significantly lower than in infliximab and 
adalimumab groups. The cost-effectiveness ratios (CERs) in terms of ACR20 in 24 
weeks were 703 625.00, 587 776.09, and 4 119 260.82 for certulizumab pegol, etaner-
cept and infliximab groups, respectively. The same was observed in case of ACR50 
and ACR70: a strategy of drug use in certulizumab pegol and etanercept groups 
was preferable in comparison with infliximab and adalimumab groups. Budgetary 
costs for health care system were higher in case of infliximab and adalimumab. SA 
confirmed the robustness of the model ConClusions: The study demonstrated 
that certulizumab pegol and etanercept are an economically effective strategy for 
Russian patients with RA and lost response to conventional basic therapy.
PMS17
MaSt (MiniMal acceSS SPinal technologieS) verSuS oPen Surgery: 
coSt analySiS froM hoSPital PerSPective
Lukyanov V.1, Melik-Gusseinov D.1, Borgman B.2, Demourenko D.3, Mlyavykh S.4
1Center of Social Economics, Moscow, Russia, 2Medtronic International, Tolochenaz, Switzerland, 
3Medtronic LLC, Moscow, Russia, 4Scientific Research Institute of Traumatology and Orthopedics, 
Nizhniy Novgorod, Russia
objeCtives: The objective of this study was to determine and compare the resource 
consumption associated with open vs. minimal invasive surgery in patients with 
degenerative spinal disorders in the Russian hospital setting. Methods: Conducted 
cost-analysis was based on Moscow hospital setting, where resource utilization 
associated with average one-level spinal operation was determined through inter-
views with KOLs in spinal surgery. Costs were retrieved from public sources and 
hospital data for the following categories 1) hospital stay; 2) blood transfusion 3) 
consumables (suture materials, hemostatic sponges, disposable instruments); 4) 
time in the operating room; 5) spinal implants/instrumentation; and 6) complica-
tions. Results: The results of the calculations have confirmed MAST economic 
advantages over open surgery (OS). MAST was associated with fewer costs, mainly 
due to shorter stay in intensive care unit (1 vs. 2 days) and general ward (9 vs. 15 
days), no need for blood transfusion and less rate of complications. The difference 
in the duration of surgery, which depends mainly on the speed of approach and 
the installation of implantable structures, is approximately 20 minutes in favor of 
MAST. With the cost of one-hour long surgery at about 6,000 rubles (167$), excluding 
the cost of implantable structures, the use of MAST instead of OS translates into 
savings of 2,000 rubles (56$) per each surgical intervention. As for overall budget 
savings, the use of MAST translates into savings of between 14,783 ($410) and 35,000 
($970) rubles per whole hospital visit, depending on what materials and structures 
are used. ConClusions: The economic evaluation confirms economic domination 
of MAST over OS. Despite initial higher investments, MAST appears to be a cost 
saving alternative to OS, in terms of diminution of actual surgery time, reduction of 
blood transfusion costs, and prevention of post-surgery complications and shorter 
overall length of hospital stay.
validated by a registered nurse. We required 4 data elements to report a patient: date 
when fracture occurred; date when treatment began; date when treatment ended; 
and outcome (healed vs. failed, by clinical and radiological criteria). Data were used 
to calculate: days to treatment (DTT); and days on treatment (DOT). All fresh frac-
tures with DTT, DOT, and outcome are reported. Results: 5,765 patients in the reg-
istry had fresh fracture; 73% of patients (N= 4,190) are reported; 13% of patients were 
lost to follow-up; 11% withdrew or were noncompliant; and 3% died or are miss-
ing outcome. Among compliant patients, HR was 96.2%. Logistic estimates of the 
odds ratio for healing are equivalent for patients aged 30 to 79 years. Nevertheless, 
patients who failed treatment were 4.5 years older than patients who healed (p < 
0.0009). DTT was significantly shorter for patients who healed (p < 0.0001). Data 
show that obesity, smoking, diabetes, vascular insufficiency, osteoporosis, cancer, 
rheumatoid arthritis, and chronic use of NSAIDs reduce HR. ConClusions: LIPUS 
mitigates the effect of age on fracture HR. Patients who used LIPUS had a 96% HR, 
whereas the expected HR averages 93%. Time to treatment was significantly shorter 
among patients who healed (p < 0.0001), suggesting it is beneficial to begin treat-
ment early. Comorbid conditions in conjunction with aging can reduce fracture HR.
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objeCtives: Using sickness fund claims data, we sought to determine osteoar-
thritis rate, drug compound class, pain therapy prevalence and type of medical 
specialists providing treatment. Methods: A group of company health-sickness 
funds (approx. 2.1 million insured patients in 2010; 2.5 million insured patients in 
2011) was used. Osteoarthritis was identified based on ICD-10 diagnoses (M16.0-9, 
M17.0-5, M17.9, M19.05, M19.25, M19.85, M19.95), then linked to prescriptions using 
the ATC codes: M01A (nonsteroidal anti-inflammatory drugs, NSAIDS), N02B (anal-
gesics and antipyretics), and N02A (opioids). Furthermore, we determined which 
groups of medical specialists prescribed the drugs. Results: Osteoarthritis was 
diagnosed in 7.8% (in 2010) and in 7.1% (in 2011) of patients. In one year, 65.4% of 
patients received a prescription for at least one drug from the analysed ATC codes: 
81.4% of patients received at least one NSAID, 36.4% an analgesic and antipyretic, 
and 27.4% an opioid. For M01A, diclofenac (54%) was most frequently prescribed; 
the proportion of coxibs was 6%. For N02B, 99% of prescriptions were for metami-
zol; 1% for paracetamol. For N02A, most prescriptions were for tramadol (29%) or 
tilidin (28%). General practitioners most frequently prescribed these drugs (42.2% 
[M01A]/46.2% [N02B]/45.9% [N02A]). ConClusions: In Germany in 2010-2011, OA 
prevalence was 7-8%, and associated with analgesic prescriptions for the majority 
of evaluated patients. Diclofenac (NSAIDs, metamizol (analgesics and antipyretics), 
and tramadol or tilidin (opioids) were most frequently prescribed in each group. 
General practitioners were the most frequent painkiller prescribers.
MuScular-Skeletal diSorderS – cost Studies
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objeCtives: Ustekinumab was approved for the treatment of psoriatic arthritis (PsA) 
in September 2013. The objective of the study was to estimate the budget impact 
of ustekinumab in the management of PsA in Greece. Methods: A budget impact 
model was developed in Excel 2010 comparing the total PsA treatment costs in the 
current treatment pathway (including golimumab, adalimumab, etanercept and inf-
liximab) with the respective costs of a treatment mix with the inclusion of usteki-
numab. Market share data for the current treatment pathway were based on market 
research. Epidemiology data were taken from the published literature. Due to lack 
of published data on resource use, a 60-field questionnaire was developed in order 
to collect local data relating to the management of PsA in Greece. Two expert panels 
were convened, one with 8 KOL dermatologists and one with 8 KOL rheumatolo-
gists, with the Delphi technique. Unit costs were retrieved from publically available 
sources. The time horizon was five years and the analysis was conducted from the 
Social Insurance Fund perspective. Results: The total number of eligible patients 
(incident and prevalent cases) was estimated to increase from 6,448 in Year 1 to 7,754 
in Year 5. The total cost in the current treatment pathway was estimated to range 
between € 48.4 million in Year 1 and € 20 million in Year 5. The costs in the treatment 
pathway including ustekinumab were € 47.8 and € 18.5 million, in the respective years. 
Therefore, the addition of ustekinumab in the treatment mix can lead to cumulative 
savings for the Social Insurance Funds of € 7.7 million, over the 5-year time horizon. 
This cost reduction is mainly attributed to the less frequent administration of usteki-
numab. ConClusions: Inclusion of ustekinumab in the treatment mix appears to 
be a cost saving treatment option in the management of PsA in Greece.
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objeCtives: To investigate the budgetary impact of increasing the patient share of 
certolizumab pegol (CZP) versus the other recommended biologic disease modifying 
anti-rheumatic drugs (bDMARDs; etanercept, adalimumab, golimumab, infliximab, 
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objeCtives: Complications in instrumental spinal surgeries (ISS) pose a consider-
able burden on patients. Necessary reoperations are associated with significant 
resource utilization and cost and from the perspective of the German Statutory 
Health Insurance (SHI). Dependable data on the frequency of reoperations and 
associated costs are lacking for Germany. The aim of this study was to estimate 
the incidence of ISS and consecutive reoperations, and to calculate the related 
costs. Methods: We conducted a retrospective claims data analysis using the 
Health Risk Institute research database, which contains anonymized claims data 
and covers approximately 5.42% of the German population. The study period 
comprised 01 January 2009 to 31 December 2011. An algorithm of operation and pro-
cedure codes (OPS) identified primary ISS and following reoperations. Reoperation 
rates were calculated for an individual period of 12 months after the primary ISS in 
2010. Annual costs for reoperations were calculated based on group comparison of 
patients with reoperation and those without reoperation (control group). Existing 
differences in cost levels in the year before the primary ISS were adjusted by the 
difference in differences approach. Results: A total of 3,316 individuals had a 
primary ISS in 2010. The reoperation rate was 9.98% (95% CI = 8.98% to 11.02%). 
Mean cost per ISS was € 11,331 for all patients (€ 13,358 reoperation group, € 11,106 
control group). The mean adjusted annual cost for a reoperation was € 11,370, with 
€ 8,432 directly attributed to the reoperation procedure and € 2,938 to excess costs 
in the first year after the primary ISS. ConClusions: The direct cost of ISS has a 
significant impact on health insurance budgets. With 10% of primary ISS patients 
requiring a reoperation in Germany, their associated annual costs are relevant from 
the SHI perspective. As demonstrated elsewhere, these cost might be partly avoid-
able by using intra-operative 3-D imaging with navigation.
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objeCtives: This study aims to estimate the incidence and costs of osteoporotic 
fractures in The Netherlands in 2010 and project them to 2030. Methods: The 
incidence and health care costs of fractures were derived from claims data of 
all health care insurers in The Netherlands. We obtained 5-year age- and gen-
der-specific costs of patients with and without fractures. Cost included hospi-
tal admission, physical therapy, occupational therapy, general practitioner and 
medication. In order to attribute fractures to osteoporosis we used a large dataset 
from a general hospital that included patients with a fracture screened with Dexa 
scan. Future projections were based on four different scenarios: 1. demographic 
scenario, 2. demographic+trend in incidence scenario, 3. demographic+trend in 
incidence+trend in cost scenario, and 4. increased treatment scenario. Results: 
Of all registered fractures 32% could be attributed to osteoporosis. In women this 
percentage was larger than in men (36 versus 21 %). This resulted in an incidence 
for all osteoporotic fractures of 964 per 100.000 in women and 245 per 100.000 in 
men for 2010. Over time (2010-2030) the overall increase in incidence of osteo-
porotic fractures was 40% (scenario 1). The increase in hip fractures ranged from 
60% (scenario 1) to 79% (scenario2). In 2010 approximately 200 million Euros was 
spend on treatment of osteoporotic fractures. The costs for osteoporotic fractures 
increased with 50% from 2010 till 2030 (scenario 1). The increase in costs for hip 
fractures was highest, ranging from 60% (scenario1) to 148% (scenario 3&4 com-
bined), resulting in cost estimates in 2030 of 161 and 249 million, respectively. 
Prevention of osteoporotic fractures in general can lead to cost-savings of 92 mil-
lion in 2030 (scenario 4 & 1 combined). ConClusions: The expected high increase 
in incidence and costs of osteoporotic fractures calls for a wider use of prevention 
and treatment options.
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objeCtives: Ankylosing spondylitis (AS) entails an individual burden to patients 
and ties up resources. This study aimed to assess the total costs of AS, includ-
ing the indirect burden of AS patients in Hungary and to obtain an overview of 
patients’ status, demographics, morbidity, working capacity and other charac-
teristics. Methods: Between January–March 2014, a questionnaire survey was 
conducted among AS patients, which was filled out voluntarily and anonymously. 
Missing data was not imputed in the analysis; considered patient number is pre-
sented next to results if lower than total patient number. Results: 152 patients 
completed the questionnaire, of which 37% were women. Mean age was 51 years 
(Standard Deviation [SD]: 13 years) and average disease duration was 17 years 
(SD: 12 years). At primary diagnosis of AS, 80% of patients had a full-time job, 2% 
a part-time job, and only 8% received disability pension. At time of survey, only 
36% of patients worked full-time, 1% part-time, and the proportion of disability 
pensioners increased to 42%. Cost calculation results* showed that the average 
annual total cost per AS patient was 5,155€ . Within this, average annual direct non-
medical cost was over 1,976€ and average annual indirect cost per patient was 
approximately 3,129€ (145 patients). Wage loss due to disability pension generated 
the highest average annual indirect cost per patient (3,290€ – 124 patients). In the 
working-age population (118 patients, 31–62 years), total average cost per patient 
was 5,996€ . ConClusions: Due to their disease, AS patients can become par-
tially or completely disabled, which imposes a significant burden directly on their 
environment and indirectly to society. Average costs were associated with disease 
duration. Patients may already be driven out from the labour market in their active 
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objeCtives: Lumbar spinal stenosis (LSS) occurs as a degeneration of the spine 
in aging populations. Treatment options comprise surgical and non-surgical 
intervention. The aim of this study was to compare annual costs between LSS 
patients treated with instrumental spinal surgery (ISS) and those non-surgically 
treated. Methods: A retrospective claims data analysis was conducted using 
anonymized claims data from the Health Risk Institute research database. The study 
period comprised 01 January 2009 to 31 December 2011. LSS patients receiving an 
ISS were compared to an age and gender matched non-operated control group with 
comparable disease state. Patients were identified by ICD-10-GM code M48.0* in the 
inpatient setting. Operation and procedure codes (OPS) were used to identify ISS. 
Comparable disease state was achieved by matching total costs in an individual 
period of 12 months before the first LSS caused hospitalization. Annual costs after 
surgical treatment were compared for LSS patients receiving ISS and those with no 
surgical treatment. Results: A total of 2,027 patients with LSS were identified in 
2010 records. Surgical treatment with ISS was applied in 542 cases whereas 1,485 
individuals received non-surgical treatment. After matching both groups for age, 
gender, and comparable disease state, 393 patients in each group were available for 
the cost comparison. Mean annual costs were € 8,458 higher in the ISS-treated group; 
clearly due to average ISS-cost of € 9,644. In contrast, costs for outpatient care and 
pharmaceuticals decrease after the surgery. ConClusions: Surgical treatment for 
LSS patients exceeds the cost of non-surgical treatment in the first year after sur-
gery. A cost offset is not achievable in this period due to the high cost of the surgical 
intervention. Nevertheless, cost savings were already observed in pharmaceutical 
therapy and outpatient care. Further research is needed to determine if overall cost 
savings could be achieved in an extended timeframe.
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objeCtives: The purpose of this study was to estimate the annual costs and the 
cost per responder for psoriatic arthritis (PsA) patients treated with apremilast, 
etanercept, and adalimumab in adults with PsA in the United States. Methods: 
Comparative efficacy data were obtained from a Bayesian network meta-analysis 
of biologic and non-biologic disease-modifying antirheumatic drugs as of October 
2013. The primary outcome was ACR20 response at Week 24. Response rate dif-
ferences from the clinical trials were assumed to be maintained for 52 weeks. US 
wholesale acquisition cost as of June 2014 and approved labeled dosing were used 
to derive drug treatment costs. Results: At Week 24, the adjusted ACR20 response 
rate was 40.3% for apremilast, 53.4% for etanercept, and 57.8% for adalimumab. 
The cost per ACR20 responder at Week 24 was $23,562 for apremilast, $30,346 for 
etanercept, and $25,978 for adalimumab. By Week 52, the cost per ACR20 responder 
was $53,704 for apremilast, $65,750 for etanercept, and $56,273 for adalimumab. The 
annual cost to achieve 100 responders was $5,370,387 for apremilast, $6,574,981 for 
etanercept, and $5,627,336 for adalimumab. ConClusions: Apremilast had the 
lowest wholesale acquisition costs per ACR20 responder and the lowest annual cost 
to achieve 100 ACR20 responders, as compared with etanercept and adalimumab 
through 52 weeks in PsA patients.
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objeCtives: Direct non-medical costs may be difficult to assess, so these are often 
disregarded in cost-of-illness studies. This analysis aims to estimate the annual 
direct non-medical costs of treating a patient with Rheumatoid Arthritis (AR) in 
Portugal, per level of disease activity. Methods: Patients with RA followed by 5 
different rheumatologists across the country, were asked to participate in a survey, 
and informed consent was given by all patients. Besides socio-economic data, the 
survey included questions regarding the following cost components: number of 
medical appointments and treatments attended by the patient and its associated 
travel expenses; expenditures related to adaptations made to their homes and the 
purchase of medical devices; amount of domiciliary support received, both paid 
and unpaid. In case of paid domiciliary support patients were also asked about the 
associated amount. That figure was then used in order to assess the value of unpaid 
domiciliary support. Disease activity was measured by the DAS28 score. Results: 
Our final sample consists of 90 patients and descriptive statistics are in line with 
RA epidemiology (73 women, mean age 56.9). The percentage of patients with low 
disease activity was 27.7%, whereas, of 43.3% and 28.8% for those with moderate 
and high disease activity, respectively. Estimated direct non-medical costs ranged 
from € 1,339 to € 5,475 per year, for patients with low and high disease activity, respec-
tively. More than 70% of these costs were related to paid and unpaid domiciliary 
support. ConClusions: Direct non-medical costs are positively associated with 
disease activity. Estimated costs have a non-negligible magnitude and are entirely 
borne by patients. Our results confirm the heavy economic burden that RA places 
on patients and their families.
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